Cargando…

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention

INTRODUCTION: The aim of the current study was to evaluate the association between lipoprotein(a) [Lp(a)] and major adverse cardiovascular events (MACEs) in patients with percutaneous coronary intervention (PCI) treatment. MATERIAL AND METHODS: This was a retrospective study. The demographics, prior...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhihao, Jiang, Chaohui, Qu, Huimin, Liang, Shuang, Yang, Jian, Wu, Hui, He, Chao, Wang, Xinan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855154/ https://www.ncbi.nlm.nih.gov/pubmed/31749864 http://dx.doi.org/10.5114/aoms.2018.79401

Ejemplares similares

Correlation between monocyte to high-density lipoprotein ratio and major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Yu, Rong, et al.
Publicado: (2021)

A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention
por: Kong, Shuting, et al.
Publicado: (2021)

Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention
por: Cai, Anping, et al.
Publicado: (2019)

Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study
por: Farshidi, Hossein, et al.
Publicado: (2018)

High‐density lipoprotein cholesterol levels are associated with major adverse cardiovascular events in male but not female patients with hypertension
por: Wang, Xiaopu, et al.
Publicado: (2021)

Eccentric hypertrophy predicts adverse events in patients undergoing percutaneous coronary intervention for acute coronary syndrome
por: Ha, Edward T., et al.
Publicado: (2021)

Elevated Baseline Serum Fibrinogen: Effect on 2‐Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention
por: Ang, Lawrence, et al.
Publicado: (2017)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
por: Ramesh, S., et al.
Publicado: (2020)

Intelligent prediction of major adverse cardiovascular events (MACCE) following percutaneous coronary intervention using ANFIS-PSO model
por: Dehdar Karsidani, Sahar, et al.
Publicado: (2022)

Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention
por: Chehrevar, Morteza, et al.
Publicado: (2022)

Factors Associated with Early Adverse Events after Coronary Artery Bypass Grafting Subsequent to Percutaneous Coronary Intervention
por: Kamal, Yasser Ali, et al.
Publicado: (2016)

The Personality and Psychological Stress Predict Major Adverse Cardiovascular Events in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention for Five Years
por: Du, Jinling, et al.
Publicado: (2016)

Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention
por: Gu, Lingyun, et al.
Publicado: (2021)

Impact of heart failure severity and major bleeding events after percutaneous coronary intervention on subsequent major adverse cardiac events
por: Ikebe, So, et al.
Publicado: (2023)

The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention
por: Safarian, Hadi, et al.
Publicado: (2014)

Evaluation of the Prognostic Role of the Wall Motion Score Index and the SYNTAX Score II in Patients with Acute Coronary Syndrome Following Percutaneous Coronary Intervention by Evaluation of Major Adverse Cardiovascular Events at 12-Month Follow-Up
por: Kong, Fanyang, et al.
Publicado: (2021)

Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention
por: Zhao, Zi-wen, et al.
Publicado: (2019)

Roles of ST2, IL‐33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention
por: Wang, Yan‐Peng, et al.
Publicado: (2017)

Using the RISK-PCI Score in the Long-Term Prediction of Major Adverse Cardiovascular Events and Mortality after Primary Percutaneous Coronary Intervention
por: Savic, Lidija, et al.
Publicado: (2019)

Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Zhang, Jianwei, et al.
Publicado: (2021)

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023)

Primary percutaneous coronary intervention in CAD patients: A comparison of major adverse cardiovascular events of second- and third-generation drug-eluting stents
por: Bibi, Salma, et al.
Publicado: (2022)

Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention
por: Huang, Zhuoshan, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor in one-year prediction of major adverse cardiac events in patients after first myocardial infarction treated with primary percutaneous coronary intervention
por: Wlazeł, Rafał N., et al.
Publicado: (2016)

The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention
por: Cheng, Lele, et al.
Publicado: (2021)

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
por: Maret-Ouda, John, et al.
Publicado: (2021)

Association between serum hemoglobin and major cardiovascular adverse event in Chinese patients with ST‐segment elevation myocardial infarction after percutaneous coronary intervention
por: Yang, Yulu, et al.
Publicado: (2021)

Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
por: Tscharre, Maximilian, et al.
Publicado: (2022)

Combination of coronary CT angiography, FFR(CT), and risk factors in the prediction of major adverse cardiovascular events in patients suspected CAD
por: Wada, Shinichi, et al.
Publicado: (2023)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

A Risk-Scoring Model to Predict One-year Major Adverse Cardiac Events after Percutaneous Coronary Intervention
por: Kassaian, Seyed-Ebrahim, et al.
Publicado: (2015)

Impact of Three-Dimensional Strain on Major Adverse Cardiovascular Events after Acute Myocardial Infarction Managed by Primary Percutaneous Coronary Intervention—A Pilot Study
por: Tomoaia, Raluca, et al.
Publicado: (2021)

Machine learning models for prediction of adverse events after percutaneous coronary intervention
por: Niimi, Nozomi, et al.
Publicado: (2022)

Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography
por: Inoue, Hiroko, et al.
Publicado: (2021)

Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease
por: Stewart, Ralph A. H., et al.
Publicado: (2016)

Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients
por: Zhu, Ling, et al.
Publicado: (2020)

The influence of testosterone on the risk of cardiovascular events after percutaneous coronary intervention
por: Chiang, Cheng-Hung, et al.
Publicado: (2022)

The association of depression following percutanous coronary intervention with adverse cardiovascular events: Protocol for a systematic review and meta-analysis
por: Liu, Yanfei, et al.
Publicado: (2019)

Serum miR-497-5p serves as a diagnostic biomarker for acute coronary syndrome and predicts the occurrence of major adverse cardiovascular events after percutaneous coronary intervention
por: Chen, Tao, et al.
Publicado: (2022)

Four‐year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
por: Miao, Benjamin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_15t2gitl060ohlaq42n6tou2f3